Organogenesis (ORGO) director receives 48,828 RSU equity award

Rhea-AI Filing Summary

Duraibabu Prathyusha reported acquisition or exercise transactions in this Form 4 filing.

Organogenesis Holdings Inc. director Prathyusha Duraibabu reported an equity award of 48,828 restricted stock units (RSUs) of Class A common stock. The RSUs were granted under the company’s 2018 Equity Incentive Plan at a price of $0.00 per unit, reflecting a compensatory grant rather than an open‑market purchase.

Each RSU represents the right to receive one share of Class A common stock upon vesting, and the award vests in full on February 15, 2027. Following this grant, Duraibabu’s directly held Class A common stock (including underlying RSUs as reported) totals 247,047 shares, highlighting an increase in her equity‑based alignment with shareholders.

Insider Trade Summary

Net Buyer: 48,828 shares

Net Buy 1 txn

Insider Duraibabu Prathyusha

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	48,828	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 247,047 shares (Direct)

Footnotes (1)

1. F1. Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027.

FAQ

What insider transaction did Organogenesis (ORGO) report for Prathyusha Duraibabu?

Organogenesis reported that director Prathyusha Duraibabu received a grant of 48,828 restricted stock units (RSUs) of Class A common stock. The award was made under the 2018 Equity Incentive Plan as a form of stock-based compensation.

At what price were the Organogenesis (ORGO) RSUs granted to Prathyusha Duraibabu?

The 48,828 RSUs granted to director Prathyusha Duraibabu were issued at a price of $0.00 per unit. This indicates a compensatory equity award rather than a market purchase, consistent with standard director or executive incentive grants.

When do Prathyusha Duraibabu’s Organogenesis (ORGO) RSUs vest?

The restricted stock units granted to Prathyusha Duraibabu vest in full on February 15, 2027. Upon vesting, each RSU will convert into one share of Organogenesis Class A common stock, subject to the terms of the 2018 Equity Incentive Plan.

How many Organogenesis (ORGO) shares does Prathyusha Duraibabu hold after this RSU grant?

After the 48,828 RSU grant, director Prathyusha Duraibabu is reported as directly owning 247,047 shares of Organogenesis Class A common stock. This total reflects her increased equity exposure and alignment with shareholder interests through stock-based compensation.

What does each Organogenesis (ORGO) RSU granted to Prathyusha Duraibabu represent?

Each restricted stock unit (RSU) granted to Prathyusha Duraibabu represents the contingent right to receive one share of Organogenesis Class A common stock upon vesting. The RSUs are issued under the company’s 2018 Equity Incentive Plan.

Is the Organogenesis (ORGO) Form 4 transaction a purchase or a grant?

The Form 4 for Organogenesis shows a grant or award acquisition, not an open-market purchase. Director Prathyusha Duraibabu received 48,828 RSUs as compensation, coded as a grant transaction rather than a buy or sell in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/20/2026 - 05:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Duraibabu Prathyusha

(Last) (First) (Middle)

C/O ORGANOGENESIS HOLDINGS INC.

85 DAN ROAD

(Street)

CANTON MA 02021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/18/2026		A(1)		48,828	A	$0	247,047	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027.

	/s/ William R. Kolb, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.